We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Manufacturers and providers have “perverse incentives” to set higher drug prices and pick pricier therapies for patients due to Medicare’s current payment structure, and the system isn’t suitable for expensive modern therapies, said Centers for Medicare and Medicaid Services Administrator Seema Verma at the American Hospital Association’s annual meeting in Washington, D.C. Read More
Prescription drug wholesaler executives were largely evasive in response to questioning about their responsibility for the opioid crisis in a contentious House subcommittee hearing Tuesday. Read More
Treatments for particularly rare diseases such as cystic fibrosis are often given special considerations by decision-makers that may lead them to impose higher thresholds for cost-effectiveness. Read More
The Drug Enforcement Administration has ordered a Shreveport, Louisiana wholesale pharmaceutical distributor to cease sales of opioids alleging that it failed to report large, suspicious orders to drugstores. Read More
Significant price cuts would be needed for three Vertex cystic fibrosis drugs to deliver benefits equal to their cost, according to an analysis by the Institute of Clinical and Economic Review. Read More
In cases where the FDA must redact information from the Clinical Study Report, the agency will handle the process in-house rather than through a third party. Read More